GNTA vs. TARA, ALGS, DYAI, CDTX, CRIS, TSBX, INAB, IKNA, OKYO, and LENZ
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Protara Therapeutics (TARA), Aligos Therapeutics (ALGS), Dyadic International (DYAI), Cidara Therapeutics (CDTX), Curis (CRIS), Turnstone Biologics (TSBX), IN8bio (INAB), Ikena Oncology (IKNA), OKYO Pharma (OKYO), and LENZ Therapeutics (LENZ). These companies are all part of the "biological products, except diagnostic" industry.
Protara Therapeutics (NASDAQ:TARA) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and community ranking.
Protara Therapeutics presently has a consensus target price of $26.50, suggesting a potential upside of 849.82%. Genenta Science has a consensus target price of $25.00, suggesting a potential upside of 635.29%. Given Genenta Science's higher probable upside, analysts clearly believe Protara Therapeutics is more favorable than Genenta Science.
38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 12.5% of Protara Therapeutics shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Protara Therapeutics had 3 more articles in the media than Genenta Science. MarketBeat recorded 7 mentions for Protara Therapeutics and 4 mentions for Genenta Science. Protara Therapeutics' average media sentiment score of 1.88 beat Genenta Science's score of 0.63 indicating that Genenta Science is being referred to more favorably in the news media.
Protara Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Protara Therapeutics' return on equity of 0.00% beat Genenta Science's return on equity.
Protara Therapeutics received 25 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 63.27% of users gave Protara Therapeutics an outperform vote.
Summary
Genenta Science beats Protara Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
